Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry
about
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loopThe molecular basis of HIV entryCharacterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.Closing the door to human immunodeficiency virus.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsEvaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitorsEvolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropismAlternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entryDifferential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitorsVicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsUse of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution.Role of CXCR4 in HIV infection and its potential as a therapeutic target.Coreceptors and HIV-1 pathogenesis.Drug resistance in HIV-1.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5Primary infection by a human immunodeficiency virus with atypical coreceptor tropismResistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 functionIncompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsHuman immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency.
P2860
Q21559473-156EE876-35FF-4627-9FED-A42D9A62D18AQ26863686-A10B1663-DF63-4A91-9797-16ADE1200D92Q30378764-30AA9C36-E98C-471A-A372-08EB6EB3245DQ30428089-7E768F46-37F2-4D8D-A56F-38D349C65CE4Q30654651-3FFE1AAA-0778-49AE-9AF7-45DA467C44AFQ33887352-121F98D3-4DAB-4297-83C8-06750AE1B8DAQ33961704-A0169F9E-F096-48AA-9CC4-AB5E707B8149Q33990552-B8089839-4ADB-4776-86F0-D40B2112EE44Q34045403-11B19426-40F6-4D04-AF6B-1C4EA03D4D07Q34055508-5CA523E9-5A71-4CE6-9859-9056BFE69DB0Q34151017-4C65598E-C5BA-4004-A98D-C7C7C9931EDCQ34574397-6A65A7EA-E26C-4B7E-AFA1-1ECE5B377425Q34641781-35889361-1A03-4974-9878-307354173D96Q34757951-F7E3AF77-8435-4C44-9AC1-21B2AAFC0C95Q35076868-48B2D466-6B59-41DD-B992-084980960EA2Q35274763-DC00F519-9F9B-4347-9286-ABE50098CEF9Q35554970-5E3473F5-FDEC-44D5-8752-07FDF65F5516Q35867443-94E58CCA-B3FA-4B5A-AAD3-D2E9E93602BFQ35904711-AB7B659B-00CA-4319-8E85-289DF866F09EQ36086642-7B2EA9A8-055D-4CC4-BE7F-B4577E04D1D9Q36476641-B70B8945-DA8E-40A1-8808-0109B2EE642DQ36827946-CE137B4D-ABD6-4EC2-AF7E-A572C0D0E5ABQ36911645-1C6D7D10-AF28-4FD8-BF91-A039A4E08299Q37421895-71FE2E43-3E76-477E-A81D-401F65F55180Q37703084-C65785DA-0692-4912-BA14-03D6EAF5EF71Q37772888-B6C8AAFC-8CB8-4F13-B917-220F0DFBD914Q37824291-A0212362-A81D-45E3-91B3-E3D73B762335Q37967710-9D56574D-5BA9-4E41-A5C4-F85061749131Q38076139-2D16B58F-AC5F-4822-A5AE-649900DF122FQ38341741-541C068F-8F5B-4F23-A606-0A5341B6B92EQ38631923-0AA65322-B2E7-486F-A09C-D1EC262E304AQ38632078-DF2E5845-495E-485F-A4E9-5CBB9D90073FQ38822845-55495618-9B2A-4BAA-A79A-42FAA9C4C288Q39361526-13FA5251-3BFF-4A01-B3CC-3923C3F71F7FQ39454698-9557D317-F1CE-4631-9106-7CF46016C746Q39471859-E5D0FF1B-3F9C-4296-AA38-84AAB510A43AQ39523186-8453EAC7-7C79-4984-8612-55EBDBF9DF36Q41808324-8D4CAA82-09D7-43B1-84CB-E3B480CFF615Q41857055-653B6DD3-D2FE-41A0-902B-A0818BA0E3E1Q42600049-D824005C-42AB-47A8-BE53-66014053AC5D
P2860
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@ast
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@en
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@nl
type
label
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@ast
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@en
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@nl
prefLabel
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@ast
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@en
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@nl
P2093
P2860
P1433
P1476
Two HIV-1 variants resistant t ...... in how they use CCR5 for entry
@en
P2093
John P Moore
Per J Klasse
Reem Berro
Rogier W Sanders
P2860
P304
P356
10.1371/JOURNAL.PPAT.1000548
P407
P577
2009-08-01T00:00:00Z